Li Kang Biomedical Co Ltd (6242) - Total Liabilities
Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) has total liabilities worth NT$212.01 Million TWD (≈ $6.68 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Li Kang Biomedical Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
Li Kang Biomedical Co Ltd - Total Liabilities Trend (2002–2025)
This chart illustrates how Li Kang Biomedical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Li Kang Biomedical Co Ltd.
Li Kang Biomedical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Li Kang Biomedical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JNK Heaters Co. Ltd
KQ:126880
|
Korea | ₩143.42 Billion |
|
Rich Sparkle Holdings Limited Ordinary Shares
NASDAQ:ANPA
|
USA | $2.85 Million |
|
Corem Property Group AB (publ)
ST:CORE-A
|
Sweden | Skr38.77 Billion |
|
Kristal Kola ve Mesrubat Sanayi Ticaret AS
IS:KRSTL
|
Turkey | TL1.03 Billion |
|
Nasus Pharma Ltd.
NYSE MKT:NSRX
|
USA | $2.24 Million |
|
SWISS PROPERTIES INV.100
F:SR1
|
Germany | €454.08 Million |
|
Tamul Multimedia Co. Ltd
KQ:093640
|
Korea | ₩32.86 Billion |
|
Dr Peng Telecom and Media Group Co Ltd
SHG:600804
|
China | CN¥7.58 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Li Kang Biomedical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Li Kang Biomedical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Li Kang Biomedical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Li Kang Biomedical Co Ltd (2002–2025)
The table below shows the annual total liabilities of Li Kang Biomedical Co Ltd from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$221.82 Million ≈ $6.99 Million |
+23.28% |
| 2024-12-31 | NT$179.93 Million ≈ $5.67 Million |
-8.65% |
| 2023-12-31 | NT$196.97 Million ≈ $6.21 Million |
+65.94% |
| 2022-12-31 | NT$118.70 Million ≈ $3.74 Million |
-4.33% |
| 2021-12-31 | NT$124.07 Million ≈ $3.91 Million |
-9.08% |
| 2020-12-31 | NT$136.46 Million ≈ $4.30 Million |
-4.57% |
| 2019-12-31 | NT$143.00 Million ≈ $4.51 Million |
+0.05% |
| 2018-12-31 | NT$142.93 Million ≈ $4.50 Million |
-4.95% |
| 2017-12-31 | NT$150.38 Million ≈ $4.74 Million |
-29.72% |
| 2016-12-31 | NT$213.96 Million ≈ $6.74 Million |
-13.18% |
| 2015-12-31 | NT$246.44 Million ≈ $7.76 Million |
+154.23% |
| 2014-12-31 | NT$96.93 Million ≈ $3.05 Million |
+10.78% |
| 2013-12-31 | NT$87.50 Million ≈ $2.76 Million |
+40.12% |
| 2012-12-31 | NT$62.45 Million ≈ $1.97 Million |
+5.18% |
| 2011-12-31 | NT$59.37 Million ≈ $1.87 Million |
+19.59% |
| 2010-12-31 | NT$49.65 Million ≈ $1.56 Million |
-60.07% |
| 2009-12-31 | NT$124.35 Million ≈ $3.92 Million |
-49.77% |
| 2008-12-31 | NT$247.58 Million ≈ $7.80 Million |
-14.72% |
| 2007-12-31 | NT$290.32 Million ≈ $9.15 Million |
-46.40% |
| 2006-12-31 | NT$541.69 Million ≈ $17.07 Million |
-4.57% |
| 2005-12-31 | NT$567.66 Million ≈ $17.88 Million |
+28.17% |
| 2004-12-31 | NT$442.91 Million ≈ $13.95 Million |
+2.50% |
| 2003-12-31 | NT$432.09 Million ≈ $13.61 Million |
+3.29% |
| 2002-12-31 | NT$418.31 Million ≈ $13.18 Million |
-- |
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. produces and sells pharmaceuticals, beauty products, and health food. It offers Chinese and Western medicines, nutritional supplements, beauty and skincare products, and daily necessities products. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was fou… Read more